Who Owns Enovis Company?

Enovis Bundle

Get Bundle
Get Full Bundle:
$15 $10
$15 $10
$15 $10
$15 $10
$15 $10
$15 $10

TOTAL:

Who Really Owns Enovis?

Understanding the ownership structure of a company is crucial for investors and stakeholders alike. Discovering the key players behind a global medical technology leader like Enovis reveals critical insights into its strategic direction and potential for growth. This exploration delves into the ownership of Enovis, a company reshaping the orthopedics landscape.

Who Owns Enovis Company?

Enovis, a company with a history rooted in strategic acquisitions and a focus on musculoskeletal health, emerged from a 2022 spin-off. This Enovis SWOT Analysis can help you understand the company's strengths and weaknesses. Today, with over $2.1 billion in reported net sales for 2024, understanding the Enovis ownership, including its major shareholders and Enovis investors, is essential for anyone evaluating Enovis stock or its future prospects. The exploration will reveal the Enovis company ownership structure, from its early days to its current public status.

Who Founded Enovis?

The story of Enovis, formerly known as Colfax Corporation, began in 1995. It was founded by brothers Mitchell and Steven Rales, who had a proven track record in business.

Their approach involved acquiring and improving existing businesses, particularly in industrial sectors. This strategy was a key part of their vision from the start.

The Rales brothers' initial focus was on industrial sectors, such as high-performance pumps. They expanded through acquisitions, including companies like IMO Industries, Inc. and Allweiler AG.

Icon

Founders

Mitchell and Steven Rales founded Colfax Corporation, which later became Enovis. They had previous experience with Danaher Corporation.

Icon

Early Strategy

The founders focused on acquiring and improving businesses. This strategy was central to their growth model.

Icon

Initial Focus

Colfax initially targeted industrial sectors. High-performance pumps were a key area of interest.

Icon

Acquisitions

Key acquisitions included IMO Industries, Inc. and Allweiler AG. These expanded the company's portfolio.

Icon

Ownership Details

Specific details on the initial equity split of the founders are not publicly available. Information on early investors is also limited.

Icon

Business System

The 'Colfax Business System' emphasized continuous improvement. This approach guided their operational enhancements.

Icon

Ownership and Early Days

Understanding the Marketing Strategy of Enovis involves knowing its origins. The founders, Mitchell and Steven Rales, established the company. The early focus was on acquiring and improving businesses. Key acquisitions and the 'Colfax Business System' played crucial roles in the company's development. Information about the initial ownership structure is not readily available. The company's history reflects a strategy of growth through acquisitions and operational improvements.

  • The Rales brothers' experience with Danaher Corporation provided a foundation.
  • The initial focus on industrial businesses set the stage for future diversification.
  • The 'Colfax Business System' was central to operational improvements.
  • Specifics on early ownership and investors are not publicly detailed.

Enovis SWOT Analysis

  • Complete SWOT Breakdown
  • Fully Customizable
  • Editable in Excel & Word
  • Professional Formatting
  • Investor-Ready Format
Get Related Template

How Has Enovis’s Ownership Changed Over Time?

The journey of understanding Who owns Enovis involves tracing its roots back to its parent company, Colfax Corporation. Colfax, initially a fluid handling company, made its public debut in May 2008. A significant shift occurred with the 2019 acquisition of DJO Global, which propelled the company into the orthopedic solutions market. This strategic move was a pivotal moment in the evolution of the company.

In March 2021, Colfax announced its plan to split into two independent, publicly traded entities to boost its strategic initiatives. This separation was finalized in April 2022, leading to the renaming of Colfax as Enovis Corporation, solely focused on medical technologies, while its fabrication technology business became ESAB Corporation. Following the separation, Enovis executed a one-for-three reverse stock split. As part of this process, Enovis shareholders received shares of ESAB, with approximately 90% of ESAB's stock distributed to Enovis shareholders.

Event Date Impact on Ownership
Initial Public Offering of Colfax May 2008 Established public ownership, laying the groundwork for future transformations.
Acquisition of DJO Global 2019 Expanded the company's footprint in the orthopedic market, influencing future ownership dynamics.
Spin-off from Colfax April 2022 Enovis became an independent, publicly traded company, altering the ownership structure significantly.

As of April 2025, Enovis Corporation, listed on the NYSE under the ticker symbol ENOV, showcases a diverse ownership structure. Institutional investors dominate, holding 93.98% of the shares, while individual investors hold 4.34%, and insiders hold 1.68%. Major institutional shareholders include BlackRock, Inc., T. Rowe Price Investment Management, Inc., and Vanguard Group Inc. As of June 4, 2025, there were 654 institutional owners and shareholders who have filed 13D/G or 13F forms with the SEC, holding a total of 88,682,584 shares. Insiders have slightly increased their holdings, rising from 1.93% to 2.03% in May 2025. For more details, you can explore the company's history and background.

Icon

Key Takeaways on Enovis Ownership

Enovis ownership is primarily held by institutional investors, reflecting its status as a publicly traded company.

  • The spin-off from Colfax Corporation was a crucial event, reshaping the ownership landscape.
  • Major institutional investors significantly influence the company's direction.
  • Understanding Enovis investors and their holdings provides insight into the company's financial health.
  • The company's stock is traded on the NYSE under the ticker symbol ENOV.

Enovis PESTLE Analysis

  • Covers All 6 PESTLE Categories
  • No Research Needed – Save Hours of Work
  • Built by Experts, Trusted by Consultants
  • Instant Download, Ready to Use
  • 100% Editable, Fully Customizable
Get Related Template

Who Sits on Enovis’s Board?

Understanding the Enovis ownership structure involves examining its board of directors and the distribution of voting power. Following the spin-off, the board of directors was restructured to guide the company's strategic direction. As of March 2022, Mitchell P. Rales was the chairman of the Board, retiring in 2023. Current directors included Liam Kelly and Matthew Trerotola, who also serves as CEO of Enovis. Other directors include Philip Okala, Clayton Perfall, Rajiv Vinnakota, Sharon Wienbar, Barbara Bodem, Angela S. Lalor, Dr. Christine Ortiz, and Brady R. Shirley. Barbara Bodem was appointed to the Audit Committee.

The board's composition reflects a mix of experience and expertise aimed at overseeing the company's operations and ensuring effective corporate governance. The board's decisions significantly influence the company's performance, making it crucial for Enovis investors to understand its structure and the individuals involved. The Enovis company ownership structure is an important factor for anyone looking to invest in Enovis stock.

Director Position Additional Information
Liam Kelly Director
Philip Okala Director
Clayton Perfall Director
Rajiv Vinnakota Director
Sharon Wienbar Director
Matthew Trerotola CEO & Director
Barbara Bodem Director Audit Committee
Angela S. Lalor Director
Dr. Christine Ortiz Director
Brady R. Shirley Director

The voting structure at Enovis is typically one-share-one-vote, which is common for companies listed on the NYSE. As of May 2025, insider ownership stands at 2.03%, while institutional ownership is at 93.98% as of April 2025. This indicates that institutional investors hold a significant portion of the voting power. For more insights into the company's strategic direction, see the Growth Strategy of Enovis.

Icon

Board of Directors and Voting Power

The board of directors plays a key role in the governance of Enovis. The voting structure is typically one-share-one-vote.

  • The board includes experienced directors like Liam Kelly and Matthew Trerotola.
  • Insider ownership is at 2.03% as of May 2025.
  • Institutional ownership is at 93.98% as of April 2025.
  • The board's decisions influence the company's performance.

Enovis Business Model Canvas

  • Complete 9-Block Business Model Canvas
  • Effortlessly Communicate Your Business Strategy
  • Investor-Ready BMC Format
  • 100% Editable and Customizable
  • Clear and Structured Layout
Get Related Template

What Recent Changes Have Shaped Enovis’s Ownership Landscape?

In the past few years, the ownership of the medical technology company, Enovis, has seen notable shifts. A key event was its separation from Colfax Corporation in April 2022, which established Enovis as an independent public entity. This strategic move significantly reshaped its ownership profile, setting the stage for subsequent developments and changes in shareholder composition. The company's focus on medical technology has also influenced its investor base and strategic direction.

A major development for Enovis was the acquisition of LimaCorporate, a global orthopedics technology company. This deal, valued at approximately €800 million (over $845 million), closed on January 3, 2024. The acquisition, comprised of €700 million in cash and €100 million in Enovis stock, is projected to boost Enovis's annual revenue to roughly $1 billion, with a substantial portion coming from the fast-growing extremities markets. This strategic move highlights Enovis's commitment to expanding its market presence and product offerings within the medical technology sector, influencing the interests of Enovis investors.

Metric Data Date
Institutional Ownership 93.98% April 2025
Institutional Holdings 118.63% May 2025
Net Sales $2.1 billion 2024
Revenue Forecast $2.06-$2.16 billion 2024

Ownership trends indicate a strong institutional investor presence in Enovis. As of April 2025, institutional investors held 93.98% of the company. While institutional holdings remained at 118.63% in May 2025, there were shifts among individual investors. For instance, MILLENNIUM MANAGEMENT LLC reduced its stake by -69.5% in Q4 2024, while CITADEL ADVISORS LLC increased its holdings by +263.2% during the same period. Furthermore, insider holdings slightly increased from 1.93% to 2.03% by May 2025. The company's financial outlook for 2024 includes net sales of $2.1 billion and a revenue forecast of approximately $2.06-$2.16 billion.

Icon Who Owns Enovis?

Enovis is primarily owned by institutional investors, holding a significant 93.98% of the company's shares as of April 2025. The company's ownership structure reflects a strong institutional interest in the medical technology sector.

Icon Enovis Stock Performance

Recent financial data shows Enovis's net sales for 2024 were $2.1 billion. The company anticipates full-year revenue to be in the range of $2.06-$2.16 billion, indicating positive financial health.

Icon Institutional Investors

Notable shifts in institutional holdings include MILLENNIUM MANAGEMENT LLC decreasing its shares and CITADEL ADVISORS LLC increasing its stake in Q4 2024. These changes highlight the dynamic nature of Enovis's investor base.

Icon Leadership Transition

Matthew Trerotola, the CEO, is set to retire at the end of February 2025, with Damien McDonald appointed as the new Chief Executive Officer. This transition marks a change in the company's leadership.

Enovis Porter's Five Forces Analysis

  • Covers All 5 Competitive Forces in Detail
  • Structured for Consultants, Students, and Founders
  • 100% Editable in Microsoft Word & Excel
  • Instant Digital Download – Use Immediately
  • Compatible with Mac & PC – Fully Unlocked
Get Related Template

Related Blogs

Data Sources

Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.